全基因组无创产前筛查的临床效用
在12114名接受常见胎儿非整倍体无创产前检测的孕妇中提供全基因组cfDNA分析,全基因组筛查检出12例(7.4%)可能存活的临床相关染色体异常,灵敏度显著高于标准筛查(100% vs 92.64%,p<0.001),特异性与标准cfDNA检测相似(99.87% vs 99.77%,p=0.064)。
要点
- 全基因组cfDNA筛查检出12例(7.4%)标准NIPT会漏检的临床相关染色体异常。
- 全基因组筛查灵敏度100%,标准筛查92.64%,差异有统计学意义(p<0.001)。
- 全基因组筛查特异性99.87%,标准cfDNA检测99.77%,差异无统计学意义(p=0.064)。
核心结论
- 全基因组cfDNA分析是产前染色体异常检测的增强筛查工具,可识别常规cfDNA检测无法检出的临床相关不平衡。
- 本研究结果证明全基因组cfDNA分析具有临床效用,较标准筛查灵敏度显著更高且保持高特异性,可能改善整体妊娠管理。
研究设计与样本
- 研究向12114名因常见胎儿非整倍体接受NIPT的孕妇提供全基因组cfDNA分析。
- 测序数据使用优化算法分析,以识别非整倍体和亚染色体异常。
主要发现
- 全基因组筛查检出12例(7.4%)可能存活的临床相关染色体异常,若仅行常规NIPT则会被漏检。
- 全基因组筛查灵敏度100% vs 标准筛查92.64%(p<0.001),差异有统计学意义。
- 全基因组筛查特异性99.87% vs 标准cfDNA检测99.77%(p=0.064),差异无统计学意义。
临床怎么用
- 原文结论认为全基因组cfDNA分析是增强的产前染色体异常筛查工具,可能改善整体妊娠管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In this study, we expanded conventional cell-free fetal DNA (cfDNA)-based non-invasive prenatal testing (NIPT) to cover the entire genome. We aimed to compare the performance of the two tests in a large general population of pregnant women, in order to assess the clinical utility of the genome-wide screening. METHOD: Genome-wide cfDNA analysis was offered to 12 114 pregnant women undergoing NIPT for common fetal aneuploidy. Sequencing data were analyzed using an algorithm optimized to identify aneuploidies and subchromosomal aberrations. RESULTS: Genome-wide screening allowed detection of 12 (7.4%) potentially viable clinically relevant chromosomal abnormalities, which would have remained overlooked if only conventional NIPT had been performed. This resulted in a statistically significant higher sensitivity (100% vs 92.64%, p < 0.001) than did standard screening. This was achieved without sacrificing the specificity of the test, which resulted similar to that obtained with standard cfDNA testing (99.87% vs 99.77%, p = 0.064). CONCLUSION: Genome-wide cfDNA analysis represents an enhanced screening tool for prenatal detection of chromosomal abnormalities, allowing identification of clinically relevant imbalances that are not detectable by conventional cfDNA testing. The results of this study demonstrate the clinical utility of genome-wide cfDNA analysis. This level of screening provides a significant higher sensitivity compared to standard screening while maintaining a high specificity, with the potential to improve overall pregnancy management. © 2017 John Wiley & Sons, Ltd.
引用
- Fiorentino F, Bono S, Pizzuti F, et al. The clinical utility of genome-wide non invasive prenatal screening. Prenat Diagn. 2017. PMID: 28423190. doi:10.1002/pd.5053
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。